reiter outperform rate share gilead
scienc increas price target follow review
oper result better expect top-line
bottom perform driven newer product biktarvi
yescarta offset legaci hiv/hcv trend
increas revenu guidanc see continu recoveri trough
earn pipelin progress filgotinib recent
galapago deal renew effort busi develop see
potenti earn reacceler multipl expans
report earn yesterday provid
updat key initi non-gaap ep vs
consensu total revenu vs consensu
driven primarili biktarvi sale vs consensu
result continu uptak yescarta sale also exceed
product sale guidanc prior guidanc
ep estim
total hiv sale us hiv sale
yoy driven volum growth qoq driven uptak
biktarvi prep price increas march descovy-bas
regim account prescript hiv treatment eu
hiv sale exclud adjust
statutori revenu clawback reserv relat sale made prior
year eu sale declin slightli qoq declin driven
broad avail gener truvada expect impact
gener moder uptak descovy-bas product
progress biktovi becom prescrib regimen
nave switch patient germani franc spain
launch uk itali recent start
total hcv sale us hcv sale
yoy driven competit lower patient
start qoq driven purchas activ
state depart correct eu hcv sale
exclud roughli adjust statutori revenu
clawback reserv eu hcv sale declin yoy qoq
yescarta sale yoy qoq
letavi ranexa sale total yoy
qoq due gener letavi introduct although letavi sale
higher sequenti due inventori dynam expect sale
declin go forward erod demand
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
non-gaap ep exclud stock-bas compens reflect adjust
compani data secur llc estim reuter
focu pipelin signific interest capsid inhibitor
earn call regard breakthrough design high unmet indic heavili
treat patient multidrug resist well regard long act properti could
focu growth opportun highlight new galapago collabor way
strengthen research engin initi data potenti futur develop
long act therapi includ prep descovi prep fda advisori committe next
week eu file use broader popul truvada prep due better safeti
filgotinib ra us file later eu file immin continu hiv franchis
growth biktarvi hit first one billion dollar quarter also note need
continu strengthen late stage portfolio galapogo collabor ipf
osteoarthr asset program filgotinib long act treatment hiv help
strengthen late stage pipelin continu look way expand
innov network earli stage collaboration/d late stage collaboration/d
price target
arriv price target appli multipl ep estim risk includ
continu slow hcv patient volum emerg credibl competit threat merck
particular failur key pipelin program hbv nash failur secur meaning revenu
opportun
expect earn growth reacceler beyond continu hiv product growth
increment contribut galapagos-partnership program fibrosi inflamm
larg cap global commercial-stag biotechnolog compani discov develop small
molecul biolog drug global leadership hiv hcv expand beyond infecti
diseas liver diseas oncolog inflammation/fibrot diseas
